Chardan Capital Maintains Buy on Avidity Biosciences, Maintains $65 Price Target

Benzinga · 05/09 10:48
Chardan Capital analyst Keay Nakae maintains Avidity Biosciences (NASDAQ:RNA) with a Buy and maintains $65 price target.